Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 |
| clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07502287 | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma(DUAL-NK-NB) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | recruiting | Phase 1 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01587300 | Neuroblastoma Biology Study | recruiting | — | 1,000 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT02298348 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma(N2013-02) | active not recruiting | Phase 1 | 18 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT02573896 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | active not recruiting | Phase 1 | 13 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02868268 | Neuroblastoma Precision Trial | active not recruiting | — | 93 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | completed | Phase 2 | 15 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05384821 | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)(MetroWilms) | recruiting | Phase 1 / Phase 2 | 28 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05556642 | Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative | recruiting | — | 500 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07048249 | Single Arm Romiplostim to Prevent CIT | recruiting | Early Phase 1 | 26 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | suspended | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05033288 | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | recruiting | — | 72 | Mayo ClinicOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02780128 | Next Generation Personalized Neuroblastoma Therapy(NEPENTHE) | terminated | Phase 1 | 66 | Yael P MosseOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | completed | Phase 3 | 1,449 | National Cancer Institute (NCI)NIH | 5 | Mar 5, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT00186992 | Radiation Therapy to Treat Musculoskeletal Tumors | active not recruiting | Phase 2 | 202 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04091295 | BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | available | — | — | Aveni FoundationOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04423484 | Therapeutic Recommendations for Nephroblastoma(GFANEPHRO20) | recruiting | — | 1,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT03581240 | An Intermediate Expanded Use Trial of DFMO | available | — | — | Giselle ShollerOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | active not recruiting | Phase 2 | 94 | Children's Oncology GroupNETWORK | 5 | Feb 18, 2026 | clinicaltrials |
| NCT04055220 | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas(REGOSTA) | recruiting | N/A | 168 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06831552 | Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma(RISE in HR NBL) | recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07399821 | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma(GLOW-FISH) | recruiting | Phase 1 / Phase 2 | 22 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04706910 | 18F-DOPA II - PET Imaging Optimization | recruiting | Phase 3 | 800 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05890781 | Engineering Immune Organoids to Study Pediatric Cancer(IMMUNEORGANOID) | recruiting | N/A | 108 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 42 | St. Jude Children's Research HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06387485 | A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning | recruiting | N/A | 150 | Ricoh USA, Inc.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03361033 | Components of Social Functioning in Survivors of Pediatric Brain Tumors | completed | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02415816 | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas | completed | N/A | 98 | St. Jude Children's Research HospitalOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT05779670 | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery(ADER) | recruiting | — | 50 | Istituto Ortopedico RizzoliOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07375563 | Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma(NB-NK-2026) | recruiting | Phase 3 | 5 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT05861245 | Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base | recruiting | N/A | 20 | QuironsaludOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
| NCT03057626 | Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma | active not recruiting | — | 376 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2026source: clinicaltrials